42 completed, 17 active not recruiting, 9 recruiting, 9 terminated. 37 Phase 3, 20 Phase 2, 15 Phase 4, 3 Phase 1.
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis RO7845860 - Relapsing Multiple Sclerosis | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 85 | 2026-11-23 | 2026-10-09 |
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) Fenebrutinib - Relapsing Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 12 | 2025-10-06 | 2026-10-13 |
| A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS) Dimethyl Fumarate Enteric-coated Capsules - Relapsing Multiple Sclerosis | Phase 4 | Not yet recruiting | Qilu Pharmaceutical (Hainan) Co., Ltd. | 50 | 2025-09-01 | 2025-08-24 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) Ublituximab - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | TG Therapeutics, Inc. | 360 | 2025-07-09 | 2026-10-23 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Ocrelizumab - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 4 | Active not recruiting | Hoffmann-La Roche | 60 | 2025-07-04 | 2026-09-30 |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. Remibrutinib oral treatment, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 400 | 2025-06-23 | 2026-10-26 |
| Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis CYB704, Ocrevus-EU, Ocrevus-US - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Sandoz | 183 | 2025-06-10 | 2026-05-29 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis rapcabtagene autoleucel (YTB323) - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2025-02-24 | 2026-09-02 |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) Obexelimab, Placebo - Relapsing Multiple Sclerosis | Phase 2 | Active not recruiting | Zenas BioPharma (USA), LLC | 93 | 2024-08-26 | 2025-11-17 |
| Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod Ozanimod - Relapsing Multiple Sclerosis | Phase 4 | Recruiting | University of Colorado, Denver | 100 | 2024-07-29 | 2025-09-18 |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) No Intervention - Relapsing Multiple Sclerosis, Multiple Sclerosis | Recruiting | TG Therapeutics, Inc. | 2000 | 2024-07-22 | 2026-09-23 | |
| A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis BMS-986374 - Relapsing Multiple Sclerosis | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 84 | 2024-05-15 | 2025-04-16 |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis Placebo, Pirtobrutinib - Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 2 | Withdrawn | Loxo Oncology, Inc. | 2024-05-01 | 2024-03-27 | |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. Tolebrutinib, Placebo, Teriflunomide - Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 2500 | 2024-04-16 | 2026-08-17 |
| A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk No intervention - Relapsing Multiple Sclerosis | Active not recruiting | TG Therapeutics, Inc. | 16 | 2024-03-26 | 2026-10-27 | |
| Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study Ofatumumab - Relapsing Multiple Sclerosis | Recruiting | Novartis Pharmaceuticals | 174 | 2023-11-27 | 2026-07-07 | |
| Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years Ofatumumab - Relapsing Multiple Sclerosis | Active not recruiting | Novartis Pharmaceuticals | 106 | 2023-07-10 | 2026-10-28 | |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab Ublituximab, Placebo - Relapsing Multiple Sclerosis | Phase 3 | Recruiting | TG Therapeutics, Inc. | 800 | 2023-06-13 | 2026-10-23 |
| A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Completed | Novartis | 113 | 2023-04-23 | 2024-05-02 |
Showing 20 of 86. Sign in to see all of them.
Multiple Sclerosis (20) · Multiple Sclerosis, Chronic Progressive (6) · Recurrence (6) · Multiple Sclerosis, Relapsing-Remitting (3) · COVID-19 (2) · Charcot-Marie-Tooth disease, Type 1F (2) · Autoimmune Diseases (1) · Cone-Rod Dystrophy 10 (1) · Demyelinating Diseases (1) · Optic Nerve Diseases (1) · Optic Neuritis (1)
Autoimmune Diseases of the Nervous System (26) · Demyelinating Autoimmune Diseases, CNS (26) · Immune System Diseases (26) · Nervous System Diseases (26) · Autoimmune Diseases (25) · Demyelinating Diseases (25) · Disease Attributes (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Chronic Disease (6) · Multiple Sclerosis (6) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Infections (2) · Lung Diseases (2)
ofatumumab (15) · teriflunomide (12) · ocrelizumab (9) · Interferon beta-1a (7) · peginterferon beta-1a (5) · Fingolimod Hydrochloride (4) · Glatiramer Acetate (4) · Natalizumab (4) · fenebrutinib (4) · ozanimod (4) · ublituximab (4) · remibrutinib (3) · Cladribine (2) · Interferon beta-1b (2) · Interferon-beta (2)
Novartis Pharmaceuticals (20) · Hoffmann-La Roche (9) · Biogen (8) · Sanofi (6) · TG Therapeutics, Inc. (5) · EMD Serono (4) · Merck KGaA, Darmstadt, Germany (4) · Novartis (4) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Celgene (2) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Cinnagen (1)
United States (52) · Spain (30) · Poland (27) · Germany (25) · United Kingdom (25) · Czechia (24) · Canada (23) · Russia (23) · Italy (22) · France (21) · Belgium (20) · Bulgaria (20) · Ukraine (20) · Slovakia (17) · Croatia (16)
Abdorreza Naser Moghadasi, Assistant Professor (1) · Bruce Cree, MD, PhD, MAS (1) · Daniel Mikol, MD, PhD (1) · Diego Centonze (1) · Elisabetta Verdun di Cantogno, MD (1) · Enrique Alvarez, MD/PhD (1) · Feng Yang, PhD (1) · Fernando Dangond, MD (1)
PMID 37652990, PMID 42546561, PMID 24613349, PMID 28002679, PMID 32511687, PMID 32690791, PMID 33724637, PMID 34904871, PMID 35672926, PMID 36163349, PMID 36792367, PMID 37148240, PMID 39290861, PMID 39307151, PMID 39965438, PMID 40202623, PMID 40258203, PMID 40554392, PMID 40629721, PMID 42832215, PMID 23472197, PMID 24221641, PMID 24794721, PMID 25073663, PMID 25265472, PMID 25432952, PMID 25551571, PMID 25698173, PMID 26195056, PMID 26879276, PMID 28183276, PMID 28450894, PMID 28607743, PMID 29104758, PMID 30043658, PMID 30181780, PMID 31492652, PMID 32757523, PMID 33307998, PMID 34418400, PMID 35266417, PMID 37094998, PMID 37606897, PMID 37691530, PMID 37769429, PMID 39018512, PMID 39460719, PMID 40107181, PMID 40245351, PMID 40248858
2019 (5), 2023 (4), 2009 (2), 2014 (2), 2018 (2), 2025 (2), 2008 (1), 2015 (1), UM1AI109565 (1)